Fate Therapeutics FATE Stock
Fate Therapeutics Price Chart
Fate Therapeutics FATE Financial and Trading Overview
| Fate Therapeutics stock price | 1.28 USD |
| Previous Close | 1.34 USD |
| Open | 1.32 USD |
| Bid | 1.91 USD x 200 |
| Ask | 3.28 USD x 200 |
| Day's Range | 1.21 - 1.33 USD |
| 52 Week Range | 0.95 - 3.23 USD |
| Volume | 1.81M USD |
| Avg. Volume | 1.48M USD |
| Market Cap | 155.74M USD |
| Beta (5Y Monthly) | 2.666 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.03 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.72 USD |
FATE Valuation Measures
| Enterprise Value | 90.97M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.3212903 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 32.788185 |
| Price/Book (mrq) | 1.1689497 |
| Enterprise Value/Revenue | 19.152 |
| Enterprise Value/EBITDA | -0.767 |
Trading Information
Fate Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.666 |
| 52-Week Change | 31.95% |
| S&P500 52-Week Change | 13.32% |
| 52 Week High | 3.23 USD |
| 52 Week Low | 0.95 USD |
| 50-Day Moving Average | 2.15 USD |
| 200-Day Moving Average | 1.99 USD |
FATE Share Statistics
| Avg. Volume (3 month) | 1.48M USD |
| Avg. Daily Volume (10-Days) | 1.96M USD |
| Shares Outstanding | 121.67M |
| Float | 107.49M |
| Short Ratio | 8.2 |
| % Held by Insiders | 1.18% |
| % Held by Institutions | 69.08% |
| Shares Short | 9.97M |
| Short % of Float | 9.25% |
| Short % of Shares Outstanding | 8.19% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2736.88% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -27.92% |
| Return on Equity (ttm) | -67.79% |
Income Statement
| Revenue (ttm) | 4.75M USD |
| Revenue Per Share (ttm) | 0.04 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -78050000 USD |
| EBITDA | -118563000 USD |
| Net Income Avi to Common (ttm) | -124433000 USD |
| Diluted EPS (ttm) | -1.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 139.13M USD |
| Total Cash Per Share (mrq) | 1.14 USD |
| Total Debt (mrq) | 74.49M USD |
| Total Debt/Equity (mrq) | 56 USD |
| Current Ratio (mrq) | 4.413 |
| Book Value Per Share (mrq) | 1.095 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -105463000 USD |
| Levered Free Cash Flow (ttm) | -50727248 USD |
Profile of Fate Therapeutics
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 12278 Scripps Summit Drive |
| ZIP | 92131 |
| Phone | 858 875 1800 |
| Website | https://www.fatetherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 161 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
Q&A For Fate Therapeutics Stock
What is a current FATE stock price?
Fate Therapeutics FATE stock price today per share is 1.28 USD.
How to purchase Fate Therapeutics stock?
You can buy FATE shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fate Therapeutics?
The stock symbol or ticker of Fate Therapeutics is FATE.
Which industry does the Fate Therapeutics company belong to?
The Fate Therapeutics industry is Biotechnology.
How many shares does Fate Therapeutics have in circulation?
The max supply of Fate Therapeutics shares is 121.67M.
What is Fate Therapeutics Price to Earnings Ratio (PE Ratio)?
Fate Therapeutics PE Ratio is now.
What was Fate Therapeutics earnings per share over the trailing 12 months (TTM)?
Fate Therapeutics EPS is -1.03 USD over the trailing 12 months.
Which sector does the Fate Therapeutics company belong to?
The Fate Therapeutics sector is Healthcare.
Fate Therapeutics FATE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25136.27 USD — |
-0.91
|
7.74B USD — | 24872.41 USD — | 25423.09 USD — | — - | 7.74B USD — |
|
US Tech Composite Total Return
XCMP
US
|
31061.46 USD — |
-0.9
|
— — | 30735.41 USD — | 31415.87 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
1937.83 USD — |
-1.05
|
— — | 1915.46 USD — | 1955.74 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7211.27 USD — |
-0.5
|
— — | 7149.19 USD — | 7238.9 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1368.29 USD — |
-0.34
|
— — | 1358.68 USD — | 1373.65 USD — | — - | — — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3020.37 USD — |
-0.22
|
— — | 2991.33 USD — | 3035.56 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
